OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Production and persistence of specific antibodies in COVID-19 patients with hematologic malignancies: role of rituximab
Chiara Cattaneo, Valeria Cancelli, Luisa Imberti, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 9
Open Access | Times Cited: 38
Chiara Cattaneo, Valeria Cancelli, Luisa Imberti, et al.
Blood Cancer Journal (2021) Vol. 11, Iss. 9
Open Access | Times Cited: 38
Showing 1-25 of 38 citing articles:
COVID-19 in patients with hematologic malignancy
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 108
Petra Langerbeins, Michael Hallek
Blood (2022) Vol. 140, Iss. 3, pp. 236-252
Open Access | Times Cited: 108
Observed protection against SARS-CoV-2 reinfection following a primary infection: A Danish cohort study among unvaccinated using two years of nationwide PCR-test data
Daniela Michlmayr, Christian Holm Hansen, Sophie Gubbels, et al.
The Lancet Regional Health - Europe (2022) Vol. 20, pp. 100452-100452
Open Access | Times Cited: 52
Daniela Michlmayr, Christian Holm Hansen, Sophie Gubbels, et al.
The Lancet Regional Health - Europe (2022) Vol. 20, pp. 100452-100452
Open Access | Times Cited: 52
Persistent SARS-CoV-2 infection in immunocompromised patients facilitates rapid viral evolution: Retrospective cohort study and literature review
David Hettle, Stephanie Hutchings, Peter Muir, et al.
Clinical Infection in Practice (2022) Vol. 16, pp. 100210-100210
Open Access | Times Cited: 33
David Hettle, Stephanie Hutchings, Peter Muir, et al.
Clinical Infection in Practice (2022) Vol. 16, pp. 100210-100210
Open Access | Times Cited: 33
Rituximab‐treated patients with lymphoma develop strong CD8 T‐cell responses following COVID ‐19 vaccination
Jon Riise, Saskia Meyer, Isaac Blaas, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 6, pp. 697-708
Open Access | Times Cited: 30
Jon Riise, Saskia Meyer, Isaac Blaas, et al.
British Journal of Haematology (2022) Vol. 197, Iss. 6, pp. 697-708
Open Access | Times Cited: 30
High mortality in fully vaccinated hematologic patients treated with anti‐CD20 antibodies during the “Omicron wave” of COVID‐19 pandemic
Chiara Cattaneo, Lorenzo Masina, Chiara Pagani, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 205-207
Open Access | Times Cited: 18
Chiara Cattaneo, Lorenzo Masina, Chiara Pagani, et al.
Hematological Oncology (2022) Vol. 41, Iss. 1, pp. 205-207
Open Access | Times Cited: 18
Efficacy and safety profile of COVID-19 mRNA vaccine in patients with hematological malignancies: Systematic review and meta-analysis
Ikhwan Rinaldi, Samuel Pratama, Lowilius Wiyono, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 16
Ikhwan Rinaldi, Samuel Pratama, Lowilius Wiyono, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 16
COVID-19 in Patients with Hematologic Malignancies: Clinical Manifestations, Persistence, and Immune Response
Ivan Gur, Amir Giladi, Yonathan Nachum Isenberg, et al.
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 297-309
Open Access | Times Cited: 15
Ivan Gur, Amir Giladi, Yonathan Nachum Isenberg, et al.
Acta Haematologica (2022) Vol. 145, Iss. 3, pp. 297-309
Open Access | Times Cited: 15
Major Update 2: Antibody Response and Risk for Reinfection After SARS-CoV-2 Infection—Final Update of a Living, Rapid Review
Haley K Holmer, Katherine Mackey, Celia Fiordalisi, et al.
Annals of Internal Medicine (2022) Vol. 176, Iss. 1, pp. 85-91
Open Access | Times Cited: 15
Haley K Holmer, Katherine Mackey, Celia Fiordalisi, et al.
Annals of Internal Medicine (2022) Vol. 176, Iss. 1, pp. 85-91
Open Access | Times Cited: 15
The Possible Role of Pathogens and Chronic Immune Stimulation in the Development of Diffuse Large B-Cell Lymphoma
Lajos Gergely, M. Udvardy, Árpád Illés
Biomedicines (2024) Vol. 12, Iss. 3, pp. 648-648
Open Access | Times Cited: 2
Lajos Gergely, M. Udvardy, Árpád Illés
Biomedicines (2024) Vol. 12, Iss. 3, pp. 648-648
Open Access | Times Cited: 2
Anti-SARS-CoV-2 antibody response after 2 and 3 doses of BNT162b2 mRNA vaccine in patients with lymphoid malignancies
Simon B. Gressens, Slim Fourati, Anne Le Bouter, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 6, pp. 885.e7-885.e11
Open Access | Times Cited: 12
Simon B. Gressens, Slim Fourati, Anne Le Bouter, et al.
Clinical Microbiology and Infection (2022) Vol. 28, Iss. 6, pp. 885.e7-885.e11
Open Access | Times Cited: 12
The antibody response of haematological malignancies to COVID-19 infection and vaccination
Nicole A. Seebacher
British Journal of Cancer (2022) Vol. 126, Iss. 5, pp. 691-692
Open Access | Times Cited: 11
Nicole A. Seebacher
British Journal of Cancer (2022) Vol. 126, Iss. 5, pp. 691-692
Open Access | Times Cited: 11
Real-World Third COVID-19 Vaccine Dosing and Antibody Response in Patients With Hematologic Malignancies
Michael A. Thompson, Sigrun Hallmeyer, Veronica Fitzpatrick, et al.
Journal of patient-centered research and reviews (2022) Vol. 9, Iss. 3, pp. 149-157
Open Access | Times Cited: 11
Michael A. Thompson, Sigrun Hallmeyer, Veronica Fitzpatrick, et al.
Journal of patient-centered research and reviews (2022) Vol. 9, Iss. 3, pp. 149-157
Open Access | Times Cited: 11
Antibody response and intra‐host viral evolution after plasma therapy in COVID ‐19 patients pre‐exposed or not to B‐cell‐depleting agents
David Gachoud, Trestan Pillonel, Γεράσιμος Τσιλιμιδός, et al.
British Journal of Haematology (2022) Vol. 199, Iss. 4, pp. 549-559
Open Access | Times Cited: 11
David Gachoud, Trestan Pillonel, Γεράσιμος Τσιλιμιδός, et al.
British Journal of Haematology (2022) Vol. 199, Iss. 4, pp. 549-559
Open Access | Times Cited: 11
Advancing Luciferase-Based Antibody Immunoassays to Next-Generation Mix and Read Testing
Peter D. Burbelo, Youngmi Ji, Michael J. Iadarola
Biosensors (2023) Vol. 13, Iss. 3, pp. 303-303
Open Access | Times Cited: 6
Peter D. Burbelo, Youngmi Ji, Michael J. Iadarola
Biosensors (2023) Vol. 13, Iss. 3, pp. 303-303
Open Access | Times Cited: 6
Bendamustine impairs humoral but not cellular immunity to SARS-CoV-2 vaccination in rituximab-treated B-cell lymphoma–affected patients
Anna Vanni, Lorenzo Salvati, Alessio Mazzoni, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
Anna Vanni, Lorenzo Salvati, Alessio Mazzoni, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 6
IgG antibody response to SARS-CoV-2 infection and its influencing factors in lymphoma patients
Huan Xie, Jing Zhang, Ran B. Luo, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Huan Xie, Jing Zhang, Ran B. Luo, et al.
BMC Immunology (2024) Vol. 25, Iss. 1
Open Access | Times Cited: 1
Exposure to obinutuzumab does not affect outcomes of SARS ‐CoV ‐2 infection in vaccinated patients with newly diagnosed advanced‐stage follicular lymphoma
Antonio Pinto, M. Caltagirone, Marco Johannes Battista, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
Antonio Pinto, M. Caltagirone, Marco Johannes Battista, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
Observed Protection Against SARS-CoV-2 Reinfection Following a Primary Infection: A Danish Cohort Study Using Two Years of Nationwide PCR-Test Data
Daniela Michlmayr, Christian Holm Hansen, Sophie Gubbels, et al.
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 6
Daniela Michlmayr, Christian Holm Hansen, Sophie Gubbels, et al.
SSRN Electronic Journal (2022)
Closed Access | Times Cited: 6
Point of care detection of SARS-CoV-2 antibodies and neutralisation capacity—lateral flow immunoassay evaluation compared to commercial assay to inform potential role in therapeutic and surveillance practices
Jonathan McGrath, Laura O’Doherty, Niall Conlon, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 3
Jonathan McGrath, Laura O’Doherty, Niall Conlon, et al.
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 3
Indolent lymphoma care delivery and outcomes during the COVID‐19 pandemic in Ontario, Canada
Inna Y. Gong, Anca Prica, Zharmaine Ante, et al.
British Journal of Haematology (2023) Vol. 204, Iss. 3, pp. 805-814
Closed Access | Times Cited: 3
Inna Y. Gong, Anca Prica, Zharmaine Ante, et al.
British Journal of Haematology (2023) Vol. 204, Iss. 3, pp. 805-814
Closed Access | Times Cited: 3
Recovery from severe persistent COVID-19 without evidence of an anti-SARS-CoV-2 antibody response in a man with mantle cell lymphoma treated with rituximab
Hiroshi Horiuchi, Hiroaki Sasaki, Kazuhito Miyazaki, et al.
Journal of Infection and Chemotherapy (2021) Vol. 28, Iss. 2, pp. 329-332
Open Access | Times Cited: 8
Hiroshi Horiuchi, Hiroaki Sasaki, Kazuhito Miyazaki, et al.
Journal of Infection and Chemotherapy (2021) Vol. 28, Iss. 2, pp. 329-332
Open Access | Times Cited: 8
Immune response to COVID-19 vaccines in people with immunodeficiencies
Emily Ricotta, Mackenzie Zendt, Fausto Bustos Castillo, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Emily Ricotta, Mackenzie Zendt, Fausto Bustos Castillo, et al.
Research Square (Research Square) (2023)
Open Access | Times Cited: 2
Severe COVID pneumonia and undetectable B cells after vaccination in patients previously treated with rituximab: a case series
Takashi Sakano, Edward A. Bittner, Marvin G. Chang
Postgraduate Medicine (2022) Vol. 134, Iss. 2, pp. 239-243
Closed Access | Times Cited: 4
Takashi Sakano, Edward A. Bittner, Marvin G. Chang
Postgraduate Medicine (2022) Vol. 134, Iss. 2, pp. 239-243
Closed Access | Times Cited: 4
Strong Cellular Immune Response, but Not Humoral, against SARS-CoV-2 in Oncohematological Patients with Autologous Stem Cell Transplantation after Natural Infection
Lorena Vigón, Adrián Sánchez-Tornero, Sara Rodríguez-Mora, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2137-2137
Open Access | Times Cited: 4
Lorena Vigón, Adrián Sánchez-Tornero, Sara Rodríguez-Mora, et al.
Journal of Clinical Medicine (2022) Vol. 11, Iss. 8, pp. 2137-2137
Open Access | Times Cited: 4
Impact of the COVID-19 pandemic on the diagnosis and treatment of onco-hematologic patients: a discussion paper
Emilio Bouza, Miguel Martı́n, Jose Enrique Alés, et al.
Revista Española de Quimioterapia (2022) Vol. 36, Iss. 1, pp. 1-25
Open Access | Times Cited: 4
Emilio Bouza, Miguel Martı́n, Jose Enrique Alés, et al.
Revista Española de Quimioterapia (2022) Vol. 36, Iss. 1, pp. 1-25
Open Access | Times Cited: 4
